Drug maker Merck & Co. Inc. (NYSE: MRK) this morning lowered its first quarter non-GAAP EPS estimate to $0.95-$0.98, well below the previous consensus estimate of $1.03. For the full-year, Merck expects non-GAAP EPS of $3.75-$3.85, compared with a consensus estimate of $3.81.
The company also said that 2012 revenues “to be at or near 2011 levels on a constant currency basis. At current exchange rates, sales would be unfavorably affected by about 2 to 3 percent.” Merck’s calculations are based on an exchange rate of $1.31/euro.
The euro/dollar exchange rate is also expected to have a negative impact of -1% to -2% on first quarter earnings. Full-year sales are expected to get whacked by -2% to -3% as a result of the euro/dollar exchange rate.
Merck’s shares are down more than -1% in the pre-market, at $38.02 in a 52-week range of $29.47-$39.43.
Sponsored: Want to Retire Early? Start Here
Want retirement to come a few years earlier than you’d planned? Orare you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
